TW200640492A - Sustained release composition of protein drug - Google Patents

Sustained release composition of protein drug

Info

Publication number: TW200640492A
Authority: TW; Taiwan
Prior art keywords: protein drug; sustained release; release composition; carrier substrate; composition
Prior art date: 2005-02-21

Application number

TW095105405A

Other languages

English (en)

Inventor

Suk-Young Choi

Hoon-Sung Jeh

Original Assignee

Lg Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-21

Filing date

2006-02-17

Publication date

2006-12-01

2006-02-17 Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd

2006-12-01 Publication of TW200640492A publication Critical patent/TW200640492A/zh

Links

229940079593 drug Drugs 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 3
102000004169 proteins and genes Human genes 0.000 title abstract 3
108090000623 proteins and genes Proteins 0.000 title abstract 3
238000013268 sustained release Methods 0.000 title abstract 2
239000012730 sustained-release form Substances 0.000 title abstract 2
239000000758 substrate Substances 0.000 abstract 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095105405A 2005-02-21 2006-02-17 Sustained release composition of protein drug TW200640492A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR20050014051		2005-02-21

Publications (1)

Publication Number	Publication Date
TW200640492A true TW200640492A (en)	2006-12-01

Family

ID=36916702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095105405A TW200640492A (en)	2005-02-21	2006-02-17	Sustained release composition of protein drug

Country Status (16)

Country	Link
US (1)	US8025900B2 (zh)
EP (1)	EP1850875A4 (zh)
JP (1)	JP2008530204A (zh)
KR (1)	KR100815114B1 (zh)
CN (1)	CN101123988A (zh)
AR (1)	AR054739A1 (zh)
AU (1)	AU2006214913A1 (zh)
BR (1)	BRPI0607000A2 (zh)
CA (1)	CA2595581A1 (zh)
IL (1)	IL184558A0 (zh)
MX (1)	MX2007010131A (zh)
MY (1)	MY139088A (zh)
NZ (1)	NZ556584A (zh)
TW (1)	TW200640492A (zh)
WO (1)	WO2006088336A1 (zh)
ZA (1)	ZA200705533B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101105871B1 (ko) *	2005-09-27	2012-01-16	주식회사 엘지생명과학	인 난포자극호르몬의 안정한 용액 제형
DE102006030164A1 (de) *	2006-06-29	2008-01-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Inhalative Pulver
KR100939983B1 (ko) *	2006-10-31	2010-02-03	주식회사 엘지생명과학	히아루론산-소수성 폴리 아미노산 공중합체
CN102014873A (zh) *	2008-02-25	2011-04-13	诺瓦瓦克斯股份有限公司	糖玻璃化的病毒样颗粒
JP2011030455A (ja) *	2009-07-30	2011-02-17	Uha Mikakuto Co Ltd	トリプトファン−ヒアルロン酸食品素材及びトリプトファン高含有ペプチド−ヒアルロン酸食品素材並びにそれらの製造方法
MX391043B (es)	2011-10-25	2025-03-21	Prothena Biosciences Ltd	Formulaciones de anticuerpo y metodos.
JP6104232B2 (ja) *	2012-03-27	2017-03-29	テルモ株式会社	コーティング組成物および医療機器
ITPD20120173A1 (it)	2012-05-31	2013-12-01	Fidia Farmaceutici	"nuovo sistema di rilascio di proteine idrofobiche"
EP2938323A2 (en) *	2012-12-28	2015-11-04	Abbott Cardiovascular Systems, Inc.	Therapeutic compositions comprising antibodies
US10524489B2 (en) *	2017-07-12	2020-01-07	Zinpro Corporation	Method and composition to control rumen release of cobalt to rumen bacteria for making vitamin B12
CN117098529A (zh) *	2021-01-29	2023-11-21	天温轮特拉皮踢诗	初期突发释放受控的贮库组合物及其方法
WO2022163966A1 (ko) *	2021-01-29	2022-08-04	주식회사 티온랩테라퓨틱스	초기 방출 제어된 데포 조성물 및 이의 제조방법
KR102442807B1 (ko) *	2021-01-29	2022-09-15	주식회사 티온랩테라퓨틱스	초기 방출 제어된 데포 조성물 및 이의 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4041155A (en)	1974-10-29	1977-08-09	American Home Products Corporation	Long acting somatostatin composition
US4278661A (en) *	1979-10-12	1981-07-14	E. I. Du Pont De Nemours And Company	Purification of interferon
US5385738A (en)	1983-10-14	1995-01-31	Sumitomo Pharmaceuticals Company, Ltd.	Sustained-release injection
JPH01287041A (ja)	1988-05-13	1989-11-17	Rooman Kogyo:Kk	徐放性製剤
JPH0446200A (ja) *	1990-06-11	1992-02-17	Unitika Ltd	蛋白質固定化材料
IE912365A1 (en) *	1990-07-23	1992-01-29	Zeneca Ltd	Continuous release pharmaceutical compositions
JP3283288B2 (ja) *	1991-03-08	2002-05-20	電気化学工業株式会社	生理活性ペプチド製剤
US5416071A (en) *	1991-03-12	1995-05-16	Takeda Chemical Industries, Ltd.	Water-soluble composition for sustained-release containing epo and hyaluronic acid
JP3730667B2 (ja) *	1991-12-27	2006-01-05	武田薬品工業株式会社	注射用組成物
WO1994006452A1 (en) *	1992-09-21	1994-03-31	The Upjohn Company	Sustained-release protein formulations
US6004549A (en)	1994-12-14	1999-12-21	Schering Corporation	Crystalline protein controlled release compositions
TW403653B (en) *	1995-12-25	2000-09-01	Otsuka Pharma Co Ltd	Dry compositions
KR100236771B1 (ko) *	1997-04-01	2000-02-01	성재갑	히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) *	1997-04-01	2007-10-02	Lg Life Sciences, Ltd., Inc.	Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
TW518219B (en) *	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
US6375989B1 (en) *	1996-12-10	2002-04-23	Purdue Research Foundation	Submucosa extracts
ES2223017T5 (es) *	1997-09-23	2010-10-15	Rentschler Biotechnologie Gmbh	Formulaciones liquidas de un interferon beta.
US6458387B1 (en)	1999-10-18	2002-10-01	Epic Therapeutics, Inc.	Sustained release microspheres
US20030064105A1 (en) *	2000-08-25	2003-04-03	Myung-Jin Kim	Lipophilic-coated microparticle containing a protein drug and formulation comprising same
US6465425B1 (en) *	2000-02-10	2002-10-15	Alkermes Controlled Therapeutics, Inc.	Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
EP1260230A4 (en) *	2000-02-29	2008-08-06	Chugai Pharmaceutical Co Ltd	LONG-TERM STABILIZED PREPARATIONS
CA2518903C (en) *	2003-04-02	2013-02-05	Ares Trading S.A.	Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
CN1802171B (zh) *	2003-06-10	2010-10-13	株式会社Lg生命科学	不包含血清白蛋白的人红细胞生成素的稳定水溶液

2006
- 2006-02-17 MY MYPI20060703A patent/MY139088A/en unknown
- 2006-02-17 TW TW095105405A patent/TW200640492A/zh unknown
- 2006-02-20 AR ARP060100600A patent/AR054739A1/es not_active Application Discontinuation
- 2006-02-21 CN CNA2006800054306A patent/CN101123988A/zh active Pending
- 2006-02-21 CA CA002595581A patent/CA2595581A1/en not_active Abandoned
- 2006-02-21 EP EP06716021A patent/EP1850875A4/en not_active Withdrawn
- 2006-02-21 AU AU2006214913A patent/AU2006214913A1/en not_active Abandoned
- 2006-02-21 BR BRPI0607000-0A patent/BRPI0607000A2/pt not_active IP Right Cessation
- 2006-02-21 KR KR1020060016489A patent/KR100815114B1/ko not_active Expired - Fee Related
- 2006-02-21 JP JP2007556079A patent/JP2008530204A/ja active Pending
- 2006-02-21 MX MX2007010131A patent/MX2007010131A/es active IP Right Grant
- 2006-02-21 NZ NZ556584A patent/NZ556584A/en not_active IP Right Cessation
- 2006-02-21 US US11/816,744 patent/US8025900B2/en not_active Expired - Fee Related
- 2006-02-21 WO PCT/KR2006/000571 patent/WO2006088336A1/en not_active Ceased
2007
- 2007-07-06 ZA ZA200705533A patent/ZA200705533B/xx unknown
- 2007-07-12 IL IL184558A patent/IL184558A0/en unknown

Also Published As

Publication number	Publication date
WO2006088336A1 (en)	2006-08-24
IL184558A0 (en)	2007-10-31
CN101123988A (zh)	2008-02-13
JP2008530204A (ja)	2008-08-07
EP1850875A4 (en)	2009-11-11
MY139088A (en)	2009-08-28
KR20060093300A (ko)	2006-08-24
MX2007010131A (es)	2007-09-27
US8025900B2 (en)	2011-09-27
KR100815114B1 (ko)	2008-03-20
AR054739A1 (es)	2007-07-11
BRPI0607000A2 (pt)	2009-07-28
AU2006214913A1 (en)	2006-08-24
US20080260654A1 (en)	2008-10-23
EP1850875A1 (en)	2007-11-07
NZ556584A (en)	2009-09-25
ZA200705533B (en)	2008-08-27
CA2595581A1 (en)	2006-08-24

Publication	Publication Date	Title
TW200640492A (en)	2006-12-01	Sustained release composition of protein drug
AR047949A1 (es)	2006-03-15	Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
MY147393A (en)	2012-11-30	Administration of dipeptidyl peptidase inhibitors
BR0311285A (pt)	2007-04-27	composições e processos para revestimento de implantes médicos
TW200501277A (en)	2005-01-01	Nanofiber surfaces for use in enhanced surface area applications
TW200714294A (en)	2007-04-16	Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
AU2003299778A1 (en)	2004-07-22	Antibodies against gpr64 and uses thereof
TN2009000362A1 (en)	2010-12-31	Weekly administration of dipeptidyl peptidase inhibitors
UY27720A1 (es)	2003-10-31	Aroilpiridinonas monocíclicas,
WO2006137934A3 (en)	2009-03-05	Purposeful movement of human migratory cells away from an agent source
WO2006111524A3 (en)	2006-12-07	Il-21 variants
TW200716589A (en)	2007-05-01	Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
AU2003288977A1 (en)	2004-06-07	Transdermal delivery of fentanyl
UA100255C2 (uk)	2012-12-10	Фармацевтична композиція
BR0308486A (pt)	2005-01-18	Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
BRPI0410861A (pt)	2006-05-23	métodos e composições para a produção de aminoácidos
NZ601592A (en)	2014-02-28	Recombinant elastase proteins and methods of manufacturing and use thereof
IL171875A0 (en)	2006-04-10	Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
WO2007081419A3 (en)	2008-01-03	Compositions and methods related to anti-fgf agents
AR061155A1 (es)	2008-08-06	Preparaciones liofilizadas de pantoprazol sodico para inyeccion
WO2007123686A3 (en)	2008-07-03	Dpp inhibitors and uses thereof
DE602005008607D1 (de)	2008-09-11	Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
GEP20084463B (en)	2008-08-25	Use of the distrontium salt of the acid 2-[n,n-di(carboxy methyl) amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylate for the production of medicaments for the treatment of gastro-duodenal pain
TR200706209T1 (tr)	2007-12-24	Alfuzosinin kontrollü salınım formülasyonları.
AU2003233404A1 (en)	2003-09-29	Tissue engineering